Reports

Sale

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market

Global Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market: By Disease Indication: Arthritis, Migraine, Ophthalmic Diseases, Others; By Drugs: Over-the-Counter Drugs, Prescription; By Route of Administration: Oral, Parenteral; By Distribution Channels: Hospital Pharmacy, Others; Regional Analysis; Supplier Landscape; 2024-2032

Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size

The global non-steroidal anti-inflammatory drugs (NSAIDs) market attained a value of USD 21.70 billion in 2023, driven by a shift from opioid analgesics use of NSAIDs and enhancing client’s knowledge of their side effects across the globe. The market is further expected to grow at a CAGR of 5.40% between 2024 and 2032 to reach a value of USD 34.84 billion by 2032.

 

Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Outlook

  • The market value is expected to grow with a preference for NSAIDs for mild to moderate pain treatment and avoid opioid dependence.
  • Rising incidence of arthritis, muscle pain, premenstrual menstrual cramps, and injuries like sprains are likely to augment the market demand for NSAIDs in the forecast period.
  • The market is witnessing more investments intended to improve access to NSAIDs. Such efforts are expected to boost the market value in coming years.

 

Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Overview

Non-steroidal anti-inflammatory drugs (NSAIDs) are often used to alleviate pain, inflammation, and fever. Chronic pain being a long-term problem, that worsens health and economic issues due to reduced productivity and higher health costs. NSAIDs work by reducing prostaglandins (compounds that involved in causing pain and inflammation). These drugs help manage pain from arthritis, muscle pain, headache, premenstrual menstrual cramps, and injuries like sprains and strains. They are available without over the counter as common pain relievers like ibuprofen (Advil, Motrin) and naproxen (Aleve), and by prescription. Most NSAIDs are taken orally, but some are available as creams and gels for direct application to the skin to relieve localized pain.

 

Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Growth Drivers

Increasing Utilization of NSAIDs to Treat Multiple Conditions

With strong research and development investments, the global market for NSAIDs is set to grow in the forecast period. This growth is impacted by rising incidence of diseases that cause pain and inflammation. Bone and joint-related issues like rheumatoid arthritis and osteoarthritis comprise a major share wherein NSAIDs are used. In addition, surge in surgical procedures in hospitals is leading increased adoption of NSAIDs. Pain disorders and the aging population prone to various diseases are also increasing the need for the drugs. Additionally, rising support for pain management from end-users, helped by government and healthcare policies, ensures market expansion.

 

Increased Preference Over Opioids to Boost the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Demand

Despite the widespread use of opioids for pain relief, there is a growing trend towards prescribing NSAIDs due to the harmful effects of opioids. This has led to a push for safer pain management options. The American Academy of Family Physicians advises over-the-counter drugs like ibuprofen and naproxen as the primary treatment for mild to moderate pain. Such recommendations are likely to further boost the NSAIDs market value in the forecast period.

 

Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Trends

Key Trends Impact
Changes in Drug Formulation to Boost Efficacy Both healthcare professionals and consumers are increasingly concerned about the long-term side effects of NSAID medication and therapy. This has led to better measures to balance risk and boost its efficacy to provide improved patient outcomes.
Rising Sports-Related Injuries As more people engage in sports and exercise, the rate of sport-related injuries has increased. Doctors often prescribe topical NSAIDs for these injuries because they effectively treat localized pain and inflammation. Therefore, the use of topical NSAIDs is rapidly growing in sports medicine and physical therapy.
Investments to Provide Effective Healthcare Facilities Improving healthcare facilities and related infrastructures are major market trends boosting market growth. More business associations and joint ventures are focusing on funding and adoption modern technologies, with both public and private organizations leading the way.
Over-the-counter (OTC) Availability and Convenience Common NSAIDs are available over the counter (OTC), making them accessible without a prescription. This easy access leads consumers to seek quick relief from pain. Forms like gels, creams, and patches allow individuals to use NSAIDs easily without needing a doctor's consultation.

 

Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Segmentation

Market Breakup by Disease Indication

  • Arthritis
  • Migraine
  • Ophthalmic Diseases
  • Others

 

Market Breakup by Drugs

  • Over-the-Counter Drugs
  • Aspirin
  • Ibuprofen
    • Naproxen
    • Celecoxib
    • Others
  • Prescription
    • Daypro
    • Indocin
    • Lodine
    • Naprosyn
    • Relafen
    • Vimovo
    • Voltaren

 

Market Breakup by Route of Administration

  • Oral
  • Parenteral

 

Market Breakup by Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

 

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Share

Arthritis Stands as the Most Dominant Category for the Forecast Period

The market segmentation based on disease indications is divided into arthritis, migraine, ophthalmic diseases, and others. Arthritis, including osteoarthritis and rheumatoid arthritis, is estimated to lead the market share in the forecast period. With chronic pain and inflammation as a common symptom, NSAID prescriptions are commonly referred by medical professionals. Ibuprofen-based products are especially popular because they work well and are easy to get. The rising prevalence of arthritis, especially in an aging population, significantly influences the NSAIDs market. NSAIDs also treat headaches and eye disorders, further boosting market growth. Ongoing research aims to meet the diverse needs of patients and healthcare providers.

 

Ibuprofen is Leading the Market Share Based on Drug Types

The market segmentation by drugs encompasses various drugs, which include over-the-counter drugs (Aspirin, Ibuprofen, Naproxen, Naproxen, Celecoxib, Others) and prescription (Daypro, Indocin, Lodine, Naprosyn, Relafen, Vimovo, Voltaren). Ibuprofen, an OTC medication, leads the market, due to its effectiveness in treating pain and inflammation. Its various formulations cater to different patient needs. Despite this, ibuprofen is preferred over aspirin for its wider usage across different ages and therapies. Research, policy changes, and new competitors may impact the market by either reducing ibuprofen’s market share or providing opportunities for new competitors to emerge.

 

non steroidal anti inflammatory drugs nsaids market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market by Region

North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa are all included in the regional market analysis. North America holds a substantial market share for NSAIDs because of the large population and common health issues such as arthritis and chronic pain present in this region. Developed nations ensure the availability of these drugs in healthcare facilities. Proper advertising informs customers about these products. Regulatory agencies such as the Food and Drug Administration in the USA and Health Canada inspect and verify NSAIDs' safety and efficacy before and after market approval.

 

In Asia Pacific region, many large companies manufacture and distribute NSAIDs, with strong research efforts to ensure quality and safety. Asia Pacific, with its large population and increasing arthritis cases, is expected to witness rapid growth in the forecast period. Government policies on treatment pricing and coverage, along with economic development in Southeast Asia and South Asia greatly influence demand.

 

Recent Developments in the Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market

In March 2024, Endo International plc launched the first flu pill. It is called ibuprofen-famotidine 800 mg/26. They launched it through their subsidiaries Par Pharmaceutical, Inc. This new generic medication, DUEXIS®, treats rheumatoid arthritis and osteoarthritis. It also reduces the risk of ulcers in the stomach and upper intestine that come from ibuprofen. This innovation offers better treatment options for arthritis patients. It shows Endo International’s commitment to advancing drugs.

 

In May 2023, AbbVie got approval from the U. S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib). It's a new treatment for adults with moderately to severely active Crohn’s disease. This approval is expected to greatly impact the treatment of Crohn’s disease. It will give patients a new treatment choice and improve their quality of life. It is also likely to boost AbbVie’s revenues.

 

In January 2023, Sun Pharma acquired three brands from Aksigen Hospital Care, namely Disperzyme, Disperzyme-CD, and Phlogam (Trypsin BP 48 mg, Bromelain 90 mg), and Rutoside Trihydrate 100 mg. This acquisition is strategic and aims to improve Sun Pharma’s anti-inflammatory medicine range. It will provide more treatment options for patients. Sun Pharma hopes to use these well-known brands and to expand its market in anti-inflammatory drugs.

 

Leading Players in the Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market

The key features of the market report include patent analysis, and strategic initiatives such as partnerships, and collaborations analysis by the leading players. The major companies in the market are as follows:

 

Bayer AG

It is a Germany-based company that offers various NSAIDs including Aspirin (Bayer®, St. Joseph®). Ibuprofen (Motrin®, Advil®). Naproxen sodium (Aleve®)

 

Novartis AG

Established in 1996 and headquartered in Switzerland, the company is involved in the production of various medications, including NSAIDs. One notable NSAID produced by Novartis is Diclofenac.

 

Pfizer Inc.

The company was established in 1849 and has its base in New York. It deals with various NASID products like Celecoxib, and Ibuprofen.

 

Johnson & Johnson Private Limited

Based in the U.S., this company was founded in 1957. The company produces various NSAIDs which include Naproxen, Diclofenac,

 

Other companies in the market include Assertio Holdings, Inc., Amgen Inc., Lion Corporation, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, and Sanofi India Limited.

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease Indication
  • Drugs
  • Route of Administration
  • Distribution Channels
  • Region
Breakup by Disease Indication
  • Arthritis
  • Migraine
  • Ophthalmic Diseases
  • Others
Breakup by Drugs
  • Over-the-Counter Drugs
  • Prescription
Breakup by Route of Administration
  • Oral
  • Parenteral
Breakup by Distribution Channels
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy 
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Assertio Holdings, Inc.
  • Bayer AG
  • Amgen Inc
  • Lion Corporation  
  • Dr. Reddy’s Laboratories Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson Private Limited
  • GlaxoSmithKline plc 
  • Sanofi India Limited  

 

Key Questions Answered in the Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report

  • What was the global non-steroidal anti-inflammatory drugs (NSAIDs) market value in 2023?
  • What is the global non-steroidal anti-inflammatory drugs (NSAIDs) market forecast outlook for 2024-2032?
  • What are the market's major drivers, opportunities, and restraints? 
  • Which regional market is expected to lead the market share in the forecast period? 
  • What is the market segmentation based on disease indication?
  • What is the market breakup based on drugs?
  • What is the market segmentation based on route of administration?
  • What are major distribution channels in the market?
  • What are the regional markets covered in the EMR report?
  • What are the major factors aiding the global non-steroidal anti-inflammatory drugs (NSAIDs) market demand? 
  • Which country is expected to experience expedited growth during the forecast period? 
  • What are the implications of rising online pharmacy sales for the distribution of NSAIDs, and how do traditional pharmacies respond to this trend?
  • What are the major global non-steroidal anti-inflammatory drugs (NSAIDs) market trends?
  • How does the rise in the geriatric population impact the market size?
  • What are the safety and efficacy concerns associated with long-term NSAID use, and how do they influence prescribing decisions?
  • Who are the key players involved in the non-steroidal anti-inflammatory drugs (NSAIDs) market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics? 
  • What are the leading disease indications driving the non-steroidal anti-inflammatory drugs (NSAIDs) market demand?
  • Which NSAID drugs dominate the over-the-counter segment, and what factors contribute to their popularity?
  • What are the primary distribution channels through which NSAIDs are distributed to consumers, and how does each channel contribute to market penetration?

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive  Summary
3    Global Non-Steroidal Anti-Inflammatory  Drugs (NSAIDs) Market Overview 

    3.1    Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Historical Value (2017-2023) 
    3.2    Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Forecast Value (2024-2032)
4    Vendor Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors
5    Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Landscape*
    5.1    Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Developers Landscape
        5.1.1    Analysis by Year of Establishment
        5.1.2    Analysis by Company Size
        5.1.3    Analysis by Region
    5.2    Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Product Landscape 
        5.2.1    Analysis by Disease Indication
        5.2.2    Analysis by Route of Administration
6    Global Infectious Diseases Epidemiology Snapshot
    6.1    Global Infectious Disease Incidence Number Overview (2017 – 2032)
    6.2    Global Infectious Disease Incidence – by Disease (2017 – 2032) 
        6.2.1    Arthritis
        6.2.2    Migraine
        6.2.3    Ophthalmic Diseases
7    Global Non- Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Dynamics
    7.1    Market Drivers and Constraints
    7.2    SWOT Analysis
        7.2.1    Strengths
        7.2.2    Weaknesses
        7.2.3    Opportunities
        7.2.4    Threats
    7.3    PESTEL Analysis 
        7.3.1    Political 
        7.3.2    Economic 
        7.3.3    Social 
        7.3.4    Technological 
        7.3.5    Legal 
        7.3.6    Environment
    7.4    Porter’s Five Forces Model
        7.4.1    Bargaining Power of Suppliers
        7.4.2    Bargaining Power of Buyers
        7.4.3    Threat of New Entrants
        7.4.4    Threat of Substitutes
        7.4.5    Degree of Rivalry
    7.5    Key Demand Indicators 
    7.6    Key Price Indicators
    7.7    Industry Events, Initiatives, and Trends  
    7.8    Value Chain Analysis
8    Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Segmentation (2017-2032)
    8.1    Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
        8.1.1    Market Overview
        8.1.2    Arthritis
        8.1.3    Migraine
        8.1.4    Ophthalmic Diseases
        8.1.5    Others
    8.2    Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
        8.2.1    Over-the-Counter Drugs
            8.2.1.1     Aspirin
            8.2.1.2    Ibuprofen
            8.2.1.3    Naproxen
            8.2.1.4    Naproxen
            8.2.1.5    Celecoxib
            8.2.1.6    Others
        8.2.2    Prescription
            8.2.2.1    Daypro
            8.2.2.2    Indocin
            8.2.2.3    Lodine
            8.2.2.4    Naprosyn
            8.2.2.5    Relafen
            8.2.2.6    Vimovo
            8.2.2.7    Voltaren
    8.3    Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration 
        8.3.1    Market Overview
        8.3.2    Oral
        8.3.3    Parenteral
    8.4    Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels 
        8.4.1    Market Overview
        8.4.2    Hospital Pharmacy
        8.4.3    Retail Pharmacy
        8.4.4    Online Pharmacy 
        8.4.5    Others
    8.5    Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Region
        8.5.1    Market Overview
        8.5.2    North America
        8.5.3    Europe 
        8.5.4    Asia Pacific
        8.5.5    Latin America
        8.5.6    Middle East and Africa
9    North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
    9.1    North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
        9.1.1    Market Overview
        9.1.2    Arthritis
        9.1.3    Migraine
        9.1.4    Ophthalmic Diseases
        9.1.5    Others
    9.2    North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
        9.2.1    Over-the-Counter Drugs
            9.2.1.1     Aspirin
            9.2.1.2    Ibuprofen
            9.2.1.3    Naproxen
            9.2.1.4    Naproxen
            9.2.1.5    Celecoxib
            9.2.1.6    Others
        9.2.2    Prescription
            9.2.2.1    Daypro
            9.2.2.2    Indocin
            9.2.2.3    Lodine
            9.2.2.4    Naprosyn
            9.2.2.5    Relafen
            9.2.2.6    Vimovo
            9.2.2.7    Voltaren
    9.3    North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration 
        9.3.1    Market Overview
        9.3.2    Oral
        9.3.3    Parenteral
    9.4    North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels 
        9.4.1    Market Overview
        9.4.2    Hospital Pharmacy
        9.4.3    Retail Pharmacy
        9.4.4    Online Pharmacy 
        9.4.5    Others
    9.5    North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
        9.5.1    United States of America
        9.5.2    Canada
10    Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
    10.1    Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
        10.1.1    Market Overview
        10.1.2    Arthritis
        10.1.3    Migraine
        10.1.4    Ophthalmic Diseases
        10.1.5    Others
    10.2    Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
        10.2.1    Over-the-Counter Drugs
            10.2.1.1     Aspirin
            10.2.1.2    Ibuprofen
            10.2.1.3    Naproxen
            10.2.1.4    Celecoxib
            10.2.1.5    Others
        10.2.2    Prescription
            10.2.2.1    Daypro
            10.2.2.2    Indocin
            10.2.2.3    Lodine
            10.2.2.4    Naprosyn
            10.2.2.5    Relafen
            10.2.2.6    Vimovo
            10.2.2.7    Voltaren
    10.3    Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration 
        10.3.1    Market Overview
        10.3.2    Oral
        10.3.3    Parenteral
    10.4    Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels 
        10.4.1    Market Overview
        10.4.2    Hospital Pharmacy
        10.4.3    Retail Pharmacy
        10.4.4    Online Pharmacy 
        10.4.5    Others
    10.5    Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
        10.5.1    United Kingdom
        10.5.2    Germany
        10.5.3    France
        10.5.4    Italy
        10.5.5    Others
11    Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
    11.1    Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
        11.1.1    Market Overview
        11.1.2    Arthritis
        11.1.3    Migraine
        11.1.4    Ophthalmic Diseases
        11.1.5    Others
    11.2    Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
        11.2.1    Over-the-Counter Drugs
            11.2.1.1     Aspirin
            11.2.1.2    Ibuprofen
            11.2.1.3    Naproxen
            11.2.1.4    Naproxen
            11.2.1.5    Celecoxib
            11.2.1.6    Others
        11.2.2    Prescription
            11.2.2.1    Daypro
            11.2.2.2    Indocin
            11.2.2.3    Lodine
            11.2.2.4    Naprosyn
            11.2.2.5    Relafen
            11.2.2.6    Vimovo
            11.2.2.7    Voltaren
    11.3    Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration 
        11.3.1    Market Overview
        11.3.2    Oral
        11.3.3    Parenteral
    11.4    Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels 
        11.4.1    Market Overview
        11.4.2    Hospital Pharmacy
        11.4.3    Retail Pharmacy
        11.4.4    Online Pharmacy 
        11.4.5    Others
    11.5    Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
        11.5.1    China
        11.5.2    Japan
        11.5.3    India
        11.5.4    ASEAN
        11.5.5    Australia
        11.5.6    Others
12    Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
    12.1    Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
        12.1.1    Market Overview
        12.1.2    Arthritis
        12.1.3    Migraine
        12.1.4    Ophthalmic Diseases
        12.1.5    Others
    12.2    Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
        12.2.1    Over-the-Counter Drugs
            12.2.1.1     Aspirin
            12.2.1.2    Ibuprofen
            12.2.1.3    Naproxen
            12.2.1.4    Naproxen
            12.2.1.5    Celecoxib
            12.2.1.6    Others
        12.2.2    Prescription
            12.2.2.1    Daypro
            12.2.2.2    Indocin
            12.2.2.3    Lodine
            12.2.2.4    Naprosyn
            12.2.2.5    Relafen
            12.2.2.6    Vimovo
            12.2.2.7    Voltaren
    12.3    Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration 
        12.3.1    Market Overview
        12.3.2    Oral
        12.3.3    Parenteral
    12.4    Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels 
        12.4.1    Market Overview
        12.4.2    Hospital Pharmacy
        12.4.3    Retail Pharmacy
        12.4.4    Online Pharmacy 
        12.4.5    Others
    12.5    Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
        12.5.1    Brazil
        12.5.2    Argentina
        12.5.3    Mexico
        12.5.4    Others
13    Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
    13.1     Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
        13.1.1    Market Overview
        13.1.2    Arthritis
        13.1.3    Migraine
        13.1.4    Ophthalmic Diseases
        13.1.5    Others
    13.2    Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
        13.2.1    Over-the-Counter Drugs
            13.2.1.1     Aspirin
            13.2.1.2    Ibuprofen
            13.2.1.3    Naproxen
            13.2.1.4    Naproxen
            13.2.1.5    Celecoxib
            13.2.1.6    Others
        13.2.2    Prescription
            13.2.2.1    Daypro
            13.2.2.2    Indocin
            13.2.2.3    Lodine
            13.2.2.4    Naprosyn
            13.2.2.5    Relafen
            13.2.2.6    Vimovo
            13.2.2.7    Voltaren
    13.3    Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration 
        13.3.1    Market Overview
        13.3.2    Oral
        13.3.3    Parenteral
    13.4    Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels 
        13.4.1    Market Overview
        13.4.2    Hospital Pharmacy
        13.4.3    Retail Pharmacy
        13.4.4    Online Pharmacy 
        13.4.5    Others
    13.5     Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
        13.5.1    Saudi Arabia
        13.5.2    United Arab Emirates
        13.5.3    Nigeria
        13.5.4    South Africa
        13.5.5    Others
14    Regulatory Framework
    14.1    Regulatory Overview
    14.2    US FDA
    14.3    EU EMA
    14.4    INDIA CDSCO
    14.5    JAPAN PMDA
    14.6    Others
15    Patent Analysis
    15.1     Analysis by Type of Patent
    15.2     Analysis by Publication Year
    15.3     Analysis by Issuing Authority
    15.4     Analysis by Patent Age
    15.5     Analysis by CPC Analysis
    15.6     Analysis by Patent Valuation 
    15.7     Analysis by Key Players
16    Strategic Initiative
    16.1     Analysis by Partnership Instances
    16.2     Analysis by Type of Partnership
    16.3     Analysis by Leading Players
    16.4     Analysis by Geography
17    Supplier Landscape
    17.1    Market Share Analysis, By Region (Top 5 Companies)
        17.1.1    Market Share Analysis: Global
        17.1.2    Market Share Analysis: North America
        17.1.3    Market Share Analysis: Europe
        17.1.4    Market Share Analysis: Asia-Pacific
        17.1.5    Market Share Analysis: Others
    17.2    Assertio Holdings, Inc . 
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications 
    17.3    Bayer AG  
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Amgen Inc  
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Lion Corporation  
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Dr. Reddy’s Laboratories Ltd . 
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Novartis AG  
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Pfizer Inc . 
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Johnson & Johnson Private Limited  
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications 
    17.10    GlaxoSmithKline plc  
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications 
    17.11    Sanofi India Limited  
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
18    Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market – Distribution Model (Additional Insight)
    18.1     Overview 
    18.2     Potential Distributors 
    18.3     Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)

 

*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

 

**The supplier list is not exhaustive, moreover we can provide analysis of companies as per custom request.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER